REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
10:45 AM | Tuesday | Jul 21, 2026 GlobeNewsWire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW News Thumbnail
10:07 AM | Tuesday | Jul 21, 2026 PRNewsWire

The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

NEW News Thumbnail
9:58 AM | Tuesday | Jul 21, 2026 GlobeNewsWire

REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact SueWallSt

NEW News Thumbnail
3:00 AM | Monday | Jul 20, 2026 PRNewsWire

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

News Thumbnail
3:00 AM | Monday | Jul 20, 2026 PRNewsWire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

News Thumbnail
12:00 PM | Sunday | Jul 19, 2026 Newsfile Corp

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

News Thumbnail
11:30 AM | Saturday | Jul 18, 2026 Business Wire

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

News Thumbnail
6:25 AM | Saturday | Jul 18, 2026 Newsfile Corp

REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail
12:28 PM | Friday | Jul 17, 2026 GlobeNewsWire

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

News Thumbnail
10:39 AM | Friday | Jul 17, 2026 GlobeNewsWire

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewsWire

10:45 AM | Tuesday | Jul 21, 2026

news photo
Loading...

LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 14, 2026.

Read full article redirect
10:45 AM | Tuesday | Jul 21, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewsWire

LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 14, 2026.

Read full article arrow
NEW News Thumbnail
10:07 AM | Tuesday | Jul 21, 2026

The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

PRNewsWire

NEW YORK, July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read full article arrow
NEW News Thumbnail
9:58 AM | Tuesday | Jul 21, 2026

REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact SueWallSt

GlobeNewsWire

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class Period high Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class Period high

Read full article arrow
NEW News Thumbnail
3:00 AM | Monday | Jul 20, 2026

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

PRNewsWire

LOS ANGELES, July 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Read full article arrow
News Thumbnail
3:00 AM | Monday | Jul 20, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

PRNewsWire

LOS ANGELES, July 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before September 14, 2026.

Read full article arrow
News Thumbnail
12:00 PM | Sunday | Jul 19, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Newsfile Corp

New York, New York--(Newsfile Corp. - July 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period").

Read full article arrow
News Thumbnail
11:30 AM | Saturday | Jul 18, 2026

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

Business Wire

LOS ANGELES--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN.

Read full article arrow
News Thumbnail
6:25 AM | Saturday | Jul 18, 2026

REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Newsfile Corp

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (""Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been... Read more

Read full article arrow
News Thumbnail
12:28 PM | Friday | Jul 17, 2026

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

GlobeNewsWire

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).

Read full article arrow
News Thumbnail
10:39 AM | Friday | Jul 17, 2026

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

GlobeNewsWire

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options

Read full article arrow
News Thumbnail